Dunnieboy1 Posted - 40 minutes from now

$VIR over time i’ve spoke to a few directors of companies when the share price has fallen significantly and they all answer ’we are charged with running the company, not to concern ourselves with the day to day movements of the share price’. That’s why i look more at the company and follow the news, everything i see at Vir appears to be good & improving, stronger management, trials going well, restructuring went smoothly, strong balance sheet etc. I’m still a believer👍, i still believe in Santa Claus & the tooth fairy as well😂😂😂.

123_holden Posted - 1 hour ago

$VIR

DemureSweetheart Posted - 2 hours ago

$VIR

Dunnieboy1 Posted - 3 hours ago

$VIR Jason O’Byrne CFO acquired 75,000 shares on 15/11.

XBI2022 Posted - 21 hours ago

$VIR

XBI2022 Posted - 21 hours ago

$VIR We see negative reaction of vaccine stocks all over the place. Another example is Valneva which also announced positive trial results but trading at a 52 day low, or Moderna trading at a price level of February 2020. Sanofi and Pfizer which also develop, manufacture and market vaccines are sold. Also supplier to the biotech and biopharma industry as well as CDMOs - contract manufacturers - got sold (compare ThermoFisher, Lonza, Sartorius). Make America Healthier Again !!!

deezstocks3 Posted - 22 hours ago

$VIR only this company could have two positive phase 2 readouts, announce approval to move to phase 3, receive Orphan Drug designation from the EMA, and hold an investor call after a major conference… all in 72hrs… AND STILL post new all time lows for the stock price. It boggles the mind. Can someone please hit me in the head with a rock so I can wake up from a blissfully ignorant coma in 2030 when this stock is hopefully worth watching?

XBI2022 Posted - 1 day ago

$VIR Needham reiterates Vir Biotechnology VIR at Buy and maintains a price target of $19

Dunnieboy1 Posted - 1 day ago

$VIR makes you wonder at what price do we attract interest, perhaps & more than likely investors are looking for near term opportunities & continue to buy the big 5 tech stocks. If Nvidia for example disappoints the market with it’s earnings then most of both individual & institutions would suffer.

erevnon Posted - 1 day ago

Needham reiterates Vir Biotechnology $VIR at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

deezstocks3 Posted - 1 day ago

$VIR New food for thought that hasn’t been posted here yet: https://www.biospace.com/press-releases/brii-bio-delivers-first-head-to-head-comparison-of-sirna-elebsiran-and-peg-ifn%CE%B1-combination-versus-peg-ifn%CE%B1-alone-at-aaslds-the-liver-meeting-2024-demonstrating-higher-loss-of-hbv-surface-antigen-by-combining-with-sirna

Dunnieboy1 Posted - 1 day ago

$VIR Joe Stringer analyst at Needham has just issued a ’buy’ rating on Vir.

Dunnieboy1 Posted - 1 day ago

$VIR if Vir are drip feeding new shares into the market then it will weigh on the price but at least we end up with $300m in the bank albeit with some dilution, and once they’ve reached the $300m target the selling pressure end and the price may lift. That’s just a possible theory with a little background knowledge but there seems to something suppressing the price in the face of good news.

XBI2022 Posted - 1 day ago

$VIR You are right. They sell shares today.

Dunnieboy1 Posted - 1 day ago

$VIR it’s possible Vir are selling ’new shares’ into the market which may explain why the price is depressed on good news, when State Side acquired 15m shares recently they got them from a source without impacting on the price. On December 31, 2023, VIR filed a shelf registration statement with the Securities and Exchange Commission (SEC) to offer and sell up to $300 million in common stock. The offering was made through TD Cowen, which acted as the sales agent or principal. A mixed shelf offering is a financial strategy that allows companies to raise capital by registering securities in advance and then choosing when and how to offer them. Companies can issue a variety of securities, such as stocks, bonds, or warrants, and can typically offer them over a period of up to three years. This flexibility allows companies to raise funds based on market conditions or company needs.

Pharm_Hand Posted - 2 days ago

$VIR Added 3600 shares to get me up to 5000. This is way too good of a bargain with $1B cash in their bank

123_holden Posted - 2 days ago

$VIR Pick up some shares in the 6.98 range. Didn't think VIR would ever go this low. There seems to be good news and they have 1.19 billion in cash & investments which should be enough to get them through the trials. Haven't been in this stock since the COVID years. Anyway, good luck.

OpenOutcrier Posted - 2 days ago

$VIR (+2.0% pre) Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - BW https://ooc.bz/l/48609

XBI2022 Posted - 2 days ago

$VIR Vir's combination therapy, brought down viral RNA loads below quantifiable levels in 41% of treated patients at 24 weeks, and 64% of patients at 36 weeks. All patients had knockdowns of at least 99%, and many patients also showed liver function improvements. The company has already finalized its Phase 3 trial design with the FDA and plans to launch that trial in the first half of 2025. Alnylam has been partnered with the program since 2017 and can opt into a profit-sharing deal before the Phase 3 study, but has yet to make a decision, according to De Backer, CEO of Vir.

webroom Posted - 2 days ago

$VIR– New data presented at AASLD The Liver Meeting. Investor conference call November 19, 2024, at 5.15 a.m. PT / 8.15 a.m. ET –

Dunnieboy1 Posted - 2 days ago

$VIR Phase 3 trials initiated, that’s the best news we could have hoped for, one step to ’possible approval’, also a positive opinion from the European Medicines Agency.

illlicit Posted - 2 days ago

$VIR

AlertsAndNews Posted - 2 days ago

$VIR Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program https://www.businesswire.com/news/home/20241118939659/en/

QuantInsider Posted - 2 days ago

Today, I noticed some buzz around $VIR with institutions diving into short-term options. It's always fascinating to see these kinds of moves, especially when credible sources like InsiderFinance point them out. Makes you wonder what they see that we might not. How do you guys feel about where $VIR might be heading with this kind of activity?

Dunnieboy1 Posted - 2 days ago

$VIR The European Commission will evaluate the COMP’s positive opinion and consider tobevibart and elebsiran for orphan drug designation. This designation is for medicines intended to treat rare, life-threatening or chronically debilitating conditions where no other satisfactory treatment option is available, or where the medicine can be of significant benefit to those affected by a specific condition. The designation provides special incentives in the E.U., including access to specific scientific advice, fee reductions, and 10 years of market exclusivity once the medicine is approved

XBI2022 Posted - 2 days ago

$VIR

XBI2022 Posted - 2 days ago

$VIR Just bought a first position of Vir after hour.

Dunnieboy1 Posted - 2 days ago

$VIR SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has issued a positive opinion on the application for orphan drug designation of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD). This opinion is based on encouraging preliminary data from the Phase 2 SOLSTICE trial. Vir Biotechnology will present 24-week data from the Phase 2 SOLSTICE trial at AASLD The Liver Meeting® in San Diego, CA, on November 18 at 6.15 p.m. PT. An investor conference call is scheduled for

Dunnieboy1 Posted - 2 days ago

$VIR Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency Just announced

frontiere Posted - 2 days ago

$BRNS Barinthus down 13.7% today to $0.81 — bought some more on the way down — again, small volume — 200k shares DV and most of it came thru in 3 orders 9:30 94k and 10:00-10:10 30k+ — TINY. So holding / buying (personally, would buy much more if we weren’t stretched gobbling up other firesales today too!). Thesis intact. I stand by my view that RFK reaction is oversold. Question is whether we have to wait days until vicious reversal or weeks. Also look at $ABUS $VIR on a day. Big down moves even though more liquid. So not pleasant, but temporary. Personally, seen such big dips before big rips many times in biotechs. Classic Washout paper handed fast money and then fire up a spike on any good news. In micro caps just year — NCNA BNOX CMRX .